FDA OKs Boston Scientific’s New Taxus Stent

Law360, New York (October 13, 2008, 12:00 AM EDT) -- Boston Scientific Corp. has received federal clearance to bring its Taxus Liberte drug-eluting stent to market after waiting more than two years due to regulatory problems at the company’s facilities.

Boston Scientific said Friday that the U.S. Food and Drug Administration had approved its next-generation stent, and the company plans to start selling the device early next month in the United States.

The FDA sent an approvable letter to the Natick, Mass.-based company in March, stating that the firm had to meet certain requirements before its...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.